CN118490802B - A composition for improving exercise-induced myocardial injury - Google Patents
A composition for improving exercise-induced myocardial injury Download PDFInfo
- Publication number
- CN118490802B CN118490802B CN202410692200.1A CN202410692200A CN118490802B CN 118490802 B CN118490802 B CN 118490802B CN 202410692200 A CN202410692200 A CN 202410692200A CN 118490802 B CN118490802 B CN 118490802B
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- myocardial
- vitamin
- myocardial injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种改善运动心肌损伤的组合物，主要包括：大豆肽粉、支链氨基酸、牛磺酸、L‑精氨酸、谷氨酰胺、中链甘油三酯、低聚麦芽糖、葡萄糖、食用香精和维生素，通过多种不同原料的配比配置成的组合物，能够显著降低高负荷运动后心肌钙蛋白T、血清肌酸激酶、超氧化物歧化酶的浓度，并且改善心肌细胞损伤，效果显著，可以作为运动心肌损伤的保护剂。
The invention discloses a composition for improving sports myocardial injury, which mainly comprises: soybean peptide powder, branched-chain amino acids, taurine, L-arginine, glutamine, medium-chain triglycerides, maltooligosaccharides, glucose, edible flavors and vitamins. The composition is prepared by mixing a plurality of different raw materials in different proportions, can significantly reduce the concentrations of myocardial troponin T, serum creatine kinase and superoxide dismutase after high-load exercise, and improves myocardial cell damage, with significant effects, and can be used as a protective agent for sports myocardial injury.
Description
Technical Field
The invention relates to the field of health, in particular to a composition for improving exercise myocardial injury.
Background
Athletes and military operators are often exposed to high exercise loads, which often cause a series of adverse effects on the human viscera, wherein the heart is most affected, often destroying the tissue structure of the heart, causing myocardial damage, thereby affecting heart function, leading to serious arrhythmias, heart failure, reduced exercise capacity, and even increased risk of death. In recent years, researches on how to effectively improve myocardial injury caused by various reasons are in progress, and various treatment methods such as medicine intervention, supersaturated oxygen therapy, ultralow temperature therapy and the like are developed, but the methods can be truly and effectively applied to clinical practice.
The Chinese patent of CN113230356A discloses the application of kudzuvine root and celery soup in preparing a composition for resisting septicemia and myocardial injury, which uses kudzuvine root and celery as main treatment substances, and is supplemented with hawthorn, cassia seed, chinese yam, medlar, corn silk and fructo-oligosaccharide, so that myocardial tissue injury caused by septicemia can be effectively improved;
CN101766590a discloses a composition for protecting cardiac muscle from peroxidation injury, which comprises coenzyme Q, l-carnitine and octacosanol, and can reduce lipid peroxidation of cardiac muscle cell membrane, raise activity of antioxidant enzymes SOD, GSH-Px and CAT, so as to protect cardiac muscle from peroxidation injury, and delay or eliminate generation of sports fatigue.
The above-mentioned prior art can improve the condition of myocardial tissue injury, but the masses prefer to seek a rapid and convenient way to improve the myocardial injury of exercise, and a new composition for improving the myocardial injury of exercise is still needed.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a composition for improving exercise myocardial injury, which is mainly applied to high-load exercise groups, especially before military operators prepare to exercise for a long time and high intensity, the composition can accelerate the repair rate in vivo by simply taking orally, improve the activity of superoxide dismutase SOD, inhibit the rise of troponin T, and further protect myocardial peroxidation injury.
In order to achieve the above purpose, the present invention provides the following technical solutions:
The invention provides a composition for improving exercise myocardial injury, which comprises, by weight, 15-25 parts of soybean peptide powder, 10-15 parts of branched chain amino acids, 8-16 parts of taurine, 15-25 parts of L-arginine, 20-25 parts of glutamine, 10-20 parts of medium chain triglycerides and 35-40 parts of auxiliary materials.
The auxiliary materials comprise 10-25 parts of isomaltooligosaccharide, 10-25 parts of glucose, 2-6 parts of edible essence and 6-18 parts of vitamins, wherein the vitamins comprise 16-10 parts of vitamin B, 22-4 parts of vitamin B and 62-4 parts of vitamin B.
As a further preferable scheme of the invention, the composition for improving the exercise myocardial injury comprises the following raw materials, by weight, 25 parts of soybean peptide powder, 15 parts of branched-chain amino acid, 10 parts of taurine, 20 parts of L-arginine, 25 parts of glutamine, 20 parts of medium chain triglyceride and 35 parts of auxiliary materials.
The auxiliary materials comprise 25 parts of isomaltooligosaccharide, 25 parts of glucose, 6 parts of edible essence and 18 parts of vitamins, wherein the vitamins comprise 18 parts of vitamin B, 22 parts of vitamin B and 62 parts of vitamin B.
Further, the myocardial injury refers to myocardial alignment disorder, myofiber swelling and myocardial cell degeneration necrosis caused by high exercise load.
Further, the preparation method of the soybean peptide powder comprises the steps of mixing soybean protein powder and deionized water according to a weight ratio of 1:10, heating to 90 ℃ for 30 minutes, adjusting pH to 7.0, adding 2% of alkaline protease and neutral protease compound enzyme solution when the temperature is reduced to 50 ℃, carrying out enzymolysis for 5 hours at constant temperature, filtering after the reaction is finished, taking filtrate, carrying out vacuum concentration treatment, and finally obtaining the soybean peptide powder by a spray drying method.
Further, the composition for improving the exercise myocardial damage is in the form of capsules, tablets, pills, powder, oral liquid, granules or beverage.
Further, the components are weighed according to the parts by weight, mixed and stirred uniformly, and taken before the high-strength exercise of the operators.
The glutamine used in the invention can provide necessary nitrogen source for organisms, promote the synthesis of protein in muscle cells, promote the growth and differentiation of the muscle cells through the cell compatibilization, and stimulate the secretion of growth hormone, insulin and testosterone to make the organisms in a synthetic state.
The arginine used in the invention can effectively improve immunity, promote the immune system to secrete endogenous substances such as natural killer cells, phagocytes, leukotriene (interleukin-1) and the like, and is beneficial to anticancer cells and preventing virus infection. In addition, arginine is a precursor of ornithine (L-ornithine) and proline (L-proline), and proline is an important element constituting collagen, so that the arginine is supplemented to the health care of serious trauma, burn and the like which needs a large amount of tissue repair, has obvious help, and has the effect of reducing infection and inflammation.
Vitamin B1, also known as thiamine, used in the invention is the earliest discovered water-soluble vitamin, and is mainly used as coenzyme to maintain normal glucose metabolism of human body, convert glucose into heat, provide energy for the body, protect and regulate the nervous system, improve mental state, regulate water-salt metabolism, maintain heart function, promote gastrointestinal peristalsis, increase appetite and improve dyspepsia.
Compared with the prior art, the invention has the following beneficial effects:
(1) Aiming at the characteristics of vigorous metabolism, huge physical consumption and myocardial injury of athletes and military operators, the composition is prepared into tablets or capsules by reasonably proportioning soybean peptide powder, branched chain amino acid, taurine, L-arginine, glutamine, medium chain triglyceride, oligomeric maltose, glucose, edible essence, vitamin B1, vitamin B2 and vitamin B6, so that the myofiber tissues are effectively improved, and important tissues such as heart, muscle and the like of the crowd are protected.
(2) Experiments prove that the composition can obviously reduce the serum myocardial injury marker level (cardiac troponin T, serum creatine kinase and superoxide dismutase) and relieve the oxidative stress level so as to achieve the purpose of protecting cardiac muscle, and the protective effect of the low, medium and high dose composition on the exercise cardiac muscle can be observed in pathological examination.
(3) The composition has wide sources of various raw materials and auxiliary materials, and can be produced by a mature method, so that the pharmaceutical composition is convenient for industrialized mass production. In addition, the composition can be prepared into capsules, tablets, oral liquid, beverages or other dosage forms by changing the bearing mode of the composition, so that the composition has stable curative effect and is convenient to use.
Drawings
FIG. 1 is a graph showing the effect of the composition on serum cardiac troponin T and serum histone creatine kinase.
FIG. 2 is a graph showing the effect of the composition on lactate dehydrogenase.
FIG. 3 is a graph showing the effect of the composition on myocardial tissue oxidative stress levels.
FIG. 4 is a graph showing the effect of the composition on myocardial morphology.
Detailed Description
The technical solution of the present patent will be described in further detail with reference to the specific embodiments, and it should be noted that the following specific embodiments are described in detail as to the preferred embodiments of the present patent, but the present patent is not limited to the above embodiments, and various changes may be made within the knowledge of those skilled in the art without departing from the technical scope of the present patent, and the following components are calculated according to parts by weight unless specifically noted.
In embodiments of the invention, words such as "exemplary" or "such as" are used to mean serving as an example, instance, or illustration. Any embodiment or design described herein as "exemplary" or "e.g." in an embodiment should not be taken as preferred or advantageous over other embodiments or designs. Rather, the use of words such as "exemplary" or "such as" is intended to present related concepts in a concrete fashion.
The mice used in the following examples were male, purchased from Shanghai Bikeke wing biotechnology Co., ltd (animal license number SCXK (Shanghai) 2023-0009), and kept in the naval specialty medical center animal house. The raw materials and the reagents are all purchased in the market. The experimental methods or related detection methods employed in the examples below employ methods known in the art, unless otherwise indicated.
It should be noted that cardiac troponin T (cTnT), serum Creatine Kinase (CK), lactate Dehydrogenase (LDH) are markers of myocardial damage, with troponin being the most sensitive and specific biochemical marker currently used for diagnosis of myocardial damage. Since cardiac myocyte injury releases troponin, plasma troponin levels can rise at the earliest within 3-4 hours after myocardial injury and can continue to rise for days, creatine kinase can be detected in the blood after myocardial injury, generally rises within 6 hours after injury, peaks at 12-24 hours, and falls to baseline levels at 24-48 hours.
Example 1
The soybean peptide powder is prepared from soybean peptide powder 25g, branched chain amino acid 15g, taurine 10g, L-arginine 20g, glutamine 25g, medium chain triglyceride 20g, isomaltooligosaccharide 25g, glucose 25g, edible essence 6g, vitamin B18g, vitamin B22g and vitamin B62g by stirring thoroughly and uniformly.
The preparation method of the soybean peptide powder comprises the following steps:
Mixing soybean protein powder and deionized water according to a weight ratio of 1:10, heating to 90 ℃, maintaining for 30 minutes, adjusting the pH value to 7.0, adding 2% of alkaline protease and neutral protease compound enzyme solution when the temperature is reduced to 50 ℃, carrying out constant-temperature enzymolysis for 5 hours, filtering after the reaction is finished, taking filtrate, carrying out vacuum concentration treatment, and finally obtaining the soybean peptide powder by using a spray drying method.
Example 2
The soybean peptide powder is prepared from 15g of soybean peptide powder, 15g of branched chain amino acid, 16g of taurine, 15g of L-arginine, 25g of glutamine, 15g of medium chain triglyceride, 25g of isomaltooligosaccharide, 25g of glucose, 6g of edible essence, 110g of vitamin B, 24g of vitamin B and 64g of vitamin B;
The preparation method of the soybean peptide powder is the same as that of example 1.
Example 3
The soybean peptide powder is prepared from soybean peptide powder 25g, branched chain amino acid 15g, taurine 10g, L-arginine 25g, glutamine 25g, medium chain triglyceride 20g, isomaltooligosaccharide 25g, glucose 25g, edible essence 6g, vitamin B16g, vitamin B22g and vitamin B62g;
The preparation method of the soybean peptide powder is the same as that of example 1.
Example 4
The soybean peptide powder is prepared from soybean peptide powder 25g, branched chain amino acid 15g, taurine 10g, L-arginine 15g, glutamine 25g, medium chain triglyceride 20g, isomaltooligosaccharide 25g, glucose 25g, edible essence 6g, vitamin B110g, vitamin B22g and vitamin B62g;
The preparation method of the soybean peptide powder is the same as that of example 1.
Example 5
The difference with example 1 is that the raw material formula comprises 10g of isomaltooligosaccharide, 10g of glucose and 2g of edible essence.
Effect test:
(1) Experimental grouping:
mice were divided into 5 groups of 10 animals each, normal, model, low, medium and high dose (using the raw material formulation of example 1) and each group was repeated 5 times.
(2) The experimental method comprises the following steps:
The experimental mice were first fed adaptively and the experiment was started 7 days later.
All mice except the normal group were run on a treadmill at a treadmill speed of 15m/min and a current stimulation intensity of 4.5mA for 30 minutes each time for 1-7d of running adaptation training. 8-28d formal experiments, except for normal groups, all mice were subjected to exhaustion experiments, first 10min at a speed of 10m/min, 15m/min for 10min, then 20m/min for exhaustion, and the current stimulation intensity was 4.5mA.
The administration time is 1 hour before each training, the administration dose is 3g/kg bw of the high dose group, 1.5g/kg bw of the medium dose and 0.75g/kg bw of the low dose.
The judgment standard of the exhaustion is that the stimulation is not effective, and the sign after running is stopped is characterized by the exhaustion such as the prone position can not be turned over freely, the breath is rapid, the mind is tired, the reaction to the physiological stimulation is slow, even no reaction exists, and the like. All animals were sacrificed the last day, blood was collected from the mouse ocular plexus vein, and biochemical, cardiomyopathy and hematological indices were measured.
The mice were sampled from the heart, cut in sagittal plane along the longitudinal axis, half of the hearts were fixed, paraffin-embedded, sectioned to observe pathological changes, the other half was homogenized on ice with 4-degree pre-chilled PBS, centrifuged at 12000rpm for 15min to collect supernatant, and the total protein concentration was measured by BCA method, while the SOD activity and MDA level in the supernatant were measured and normalized by dividing the total protein concentration to obtain relative SOD activity and MDA concentration.
(3) Experimental results:
A. effect of the composition on serum myocardial injury markers (see fig. 1 and 2):
After long-term high-load exercise, the myocardial calpain T (cTnT) and serum Creatine Kinase (CK) contents of a mouse model group are obviously increased (P < 0.01), and the low, medium and high-dose groups of the composition are obviously reduced (P < 0.01) compared with the model group, and no obvious difference exists between the low, medium and high-dose groups and a normal group, so that the composition can obviously inhibit the increase level of the troponin T and the serum creatine kinase caused by the exercise and has obvious improvement effect on myocardial injury caused by the exercise;
For Lactate Dehydrogenase (LDH), the lactate dehydrogenase content of the mouse model group increased after long-term high-load exercise, which was not significantly different from the normal group, and the composition was decreased in the low, medium, and high dose groups compared to the model group, but the difference was not significant.
B. effect of the composition on myocardial tissue oxidative stress levels (see fig. 3):
Compared with the normal group, the superoxide dismutase (SOD) level in the myocardial tissue of the mice in the model group is obviously reduced (P < 0.01), and the SOD level reduction caused by exercise can be obviously increased in the low, medium and high dose groups of the composition.
Malondialdehyde (MDA) levels in myocardial tissue were significantly elevated (P < 0.01) in mice from the model group compared to the normal group, and the composition significantly reduced MDA levels induced by exercise in low, medium and high dose groups.
C. effect of composition on myocardial morphology (see fig. 4):
after the test is finished, the normal control group has complete myocardial structure, ordered arrangement and clear transverse lines, and the interstitial tissue is not subjected to vasodilation and inflammatory cell infiltration;
The myocardial arrangement of the model group is disordered, a large amount of myofiber swelling structures are fuzzy, myocardial cell degeneration necrosis is locally visible, and bleeding and small amount of inflammatory cell infiltration are visible in the interstitium;
low dose group, still visible part of myofiber swelling, myocardial hemorrhage, local myocardial inflammatory cell infiltration and mild fibrosis;
Myocardial hemorrhage, myocardial fibrosis and inflammatory cell infiltration are seen in the medium dose group;
The high dose group showed no significant abnormalities other than a small amount of cardiomyocyte swelling.
According to the experimental results, the composition can obviously reduce the serum myocardial injury marker level and the oxidation stress level so as to achieve the purpose of protecting the cardiac muscle, and the improvement effect of the low, medium and high dose composition on the exercise cardiac muscle can be observed in pathological examination.
It will be apparent to those skilled in the art that various modifications and variations can be made to the present invention without departing from the spirit or scope of the invention. The present invention is intended to include such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (1)
1. Application of composition in preparation of medicine for improving exercise myocardial injury
Characterized in that the composition comprises the following raw materials in parts by weight:
25 parts of soybean peptide powder, 15 parts of branched chain amino acid, 10 parts of taurine and 20 parts of L-arginine
25 Parts of glutamine, 20 parts of medium chain triglyceride and 35 parts of auxiliary materials,
The auxiliary materials comprise 25 parts of isomaltooligosaccharide, 25 parts of glucose, 6 parts of edible essence,
18 Parts of vitamins, including 18 parts of vitamin B, 22 parts of vitamin B and vitamin
62 Parts of biotin B;
The myocardial injury refers to myocardial alignment disorder and myofiber swelling caused by high exercise load
Distension, myocardial cell degeneration necrosis;
The composition is prepared into the medicines for improving myocardial injury in the form of capsules, tablets, pills and powder
In the form of preparation, oral liquid, granule or beverage;
The medicine for improving myocardial injury prepared by the composition is taken 1 hour before exercise;
The preparation method of the soybean peptide powder comprises mixing soybean protein powder and deionized water according to weight ratio
Mixing at a ratio of 1:10, heating to 90deg.C for 30 min, adjusting pH to 7.0, and cooling
Adding 2% complex enzyme solution of alkaline protease and neutral protease at 50deg.C, and maintaining the temperature
Dissolving for 5-8 hr, filtering after reaction, vacuum concentrating the filtrate, and finally using
And (5) obtaining the soybean peptide powder by a spray drying method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410692200.1A CN118490802B (en) | 2024-05-31 | 2024-05-31 | A composition for improving exercise-induced myocardial injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410692200.1A CN118490802B (en) | 2024-05-31 | 2024-05-31 | A composition for improving exercise-induced myocardial injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118490802A CN118490802A (en) | 2024-08-16 |
| CN118490802B true CN118490802B (en) | 2025-03-18 |
Family
ID=92231048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410692200.1A Active CN118490802B (en) | 2024-05-31 | 2024-05-31 | A composition for improving exercise-induced myocardial injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118490802B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118987162B (en) * | 2024-10-23 | 2025-03-21 | 健码制药（广东）有限公司 | A composition for increasing myocardial vitality, improving myocardial cell metabolism and heart failure and its application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106721779A (en) * | 2016-11-15 | 2017-05-31 | 昆山国元生物科技有限公司 | Taurine sports drink containing soybean peptide |
| CN112137095A (en) * | 2020-09-27 | 2020-12-29 | 南京圣诺生物科技实业有限公司 | Sports nutritional composition and preparation method thereof |
| CN113647636A (en) * | 2021-08-19 | 2021-11-16 | 戴春玲 | Plateau anti-fatigue peptide solid beverage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2423592A1 (en) * | 2000-07-31 | 2002-02-21 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| CN100356876C (en) * | 2005-09-30 | 2007-12-26 | 北京康比特威创体育新技术发展有限公司 | Beverage for promoting sportive recovery from fatigue |
| CN101766590B (en) * | 2010-02-01 | 2011-11-16 | 北京康比特体育科技股份有限公司 | Combination for protecting peroxide injury of myocardium |
| CN104489104A (en) * | 2015-01-05 | 2015-04-08 | 新希望乳业控股有限公司 | Maca milk and preparation method thereof |
| CN105901728A (en) * | 2016-04-21 | 2016-08-31 | 姜国辉 | Composition beneficial to postoperative rehabilitation and preparation method thereof |
-
2024
- 2024-05-31 CN CN202410692200.1A patent/CN118490802B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106721779A (en) * | 2016-11-15 | 2017-05-31 | 昆山国元生物科技有限公司 | Taurine sports drink containing soybean peptide |
| CN112137095A (en) * | 2020-09-27 | 2020-12-29 | 南京圣诺生物科技实业有限公司 | Sports nutritional composition and preparation method thereof |
| CN113647636A (en) * | 2021-08-19 | 2021-11-16 | 戴春玲 | Plateau anti-fatigue peptide solid beverage |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118490802A (en) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519336A (en) | Novel uses of nitrites and nitrates and compositions containing them | |
| CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
| TWI721248B (en) | Anti-fatigue composition used for increasing endurance performance | |
| CN101953442A (en) | Health care product with function of reducing blood sugar | |
| CN118490802B (en) | A composition for improving exercise-induced myocardial injury | |
| TWI830696B (en) | Compositions for inhibiting muscle fiber degeneration | |
| WO2023005265A1 (en) | Application of nucleotide mixture in preparation of formulations for preventing or alleviating senile sarcopaenia | |
| CN106858595A (en) | One kind burn tailored version clinical nutrition formula and preparation method thereof | |
| CN105901703A (en) | A marine organism type enteral nutrition preparation used for burn patients | |
| CN105878397A (en) | Composition capable of regulating transportation stress of cattle and sheep | |
| CN113349377A (en) | Slimming probiotic soft capsule and preparation method thereof | |
| US20180279661A1 (en) | Compositions comprising medium chain triglycerides | |
| CN118058405A (en) | Pitaya fermentation magma anti-alcoholic liver-protecting drink | |
| CN106418067A (en) | Health beverage capable of replenishing physical power and relieving fatigue | |
| CN109846046A (en) | A kind of mannose-amino acid complex improving immunity | |
| CN105497106A (en) | Traditional Chinese medicine compound fermentation powder and preparation method thereof | |
| CN115153033A (en) | A compound small molecule peptide formula for regulating nutritional imbalance in the body | |
| Maimaitiaili et al. | Effects of different doses of Savda Munziq on myocardial ischemia-reperfusion injury in rats with abnormal Savda syndrome | |
| CN102210764B (en) | Application of sweet almond oil in preparing medicament for treating myocardial ischemia reperfusion injury | |
| CN106880048A (en) | A kind of antifatigue health food | |
| WO2016206363A1 (en) | Use of jilin ginseng oligopeptide in preparation of anti-oxidant food product or health care food product | |
| AU2021104246A4 (en) | Slimming probiotic soft capsule and preparation method thereof | |
| CN113142589A (en) | Liver-protecting hexapeptide composition and preparation method thereof | |
| CN1730002A (en) | Effervescence tablet preparation for replenishing nutritious elements to human being and its preparation method | |
| JP7542838B1 (en) | Atrial natriuretic peptide lowering drugs and preventive drugs and their manufacturing methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |